Unravel Biosciences and The SCN2A Foundation Announce Drug Discovery Collaboration

The SCN2A Foundation announced a research collaboration with Unravel Biosciences on January 28, 2026, to advance preclinical research for SCN2A-related disorders caused by loss-of-function mutations.15

SCN2A gene mutations result in insufficient functional protein, leading to serious neurological symptoms like epilepsy and neurodevelopmental impairment in autism.1

The collaboration evaluates therapeutic approaches in mutation-relevant lab models, focusing on RNA and protein level responses to increase functional SCN2A protein.1

Unravel uses its BioNAV™ platform and Living Molecular Twins to predict therapeutic responses for complex diseases.1

Jason Curry, Co-Founder of SCN2A Foundation, emphasized a mechanism-driven approach; Richard Novak, CEO of Unravel, highlighted precision for rare diseases.1

Sources:

1. https://www.biospace.com/press-releases/unravel-biosciences-and-the-scn2a-foundation-announce-drug-discovery-collaboration

5. https://www.businesswire.com/newsroom/industry/health/genetics